Orion
70.10 EUR
+1.01 %
14,258 following
ORNBV
NASDAQ Helsinki
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Investor consensus
+1.01 %
+10.13 %
+11.09 %
+3.09 %
-0.36 %
+42.36 %
+40.82 %
+81.70 %
+524.22 %
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
Read moreMarket cap
9.89B EUR
Turnover
7.9M EUR
P/E (adj.) (25e)
19.53
EV/EBIT (adj.) (25e)
15.35
P/B (25e)
7.71
EV/S (25e)
5.13
Dividend yield-% (25e)
2.43 %
Latest research
Latest analysis report
Released: 15.01.2026
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12.2
2026
Annual report '25
24.3
2026
General meeting '26
23.4
2026
Interim report Q1'26
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
182,827 Orion Corporation A shares converted into B shares
Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
